Corrigendum: NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis

Affiliations

Xu-Sheng Liu: Department of Nuclear Medicine and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of Medicine, Shiyan, China
Xu-Sheng Liu: Hubei Key Laboratory of Embryonic Stem Cell Research, Shiyan, China
Lu-Meng Zhou: Department of Nuclear Medicine, Huanggang Central Hospital, Huanggang, China
Ling-Ling Yuan: Department of Pathology, Taihe Hospital, Hubei University of Medicine, Shiyan, China
Yan Gao: Department of Nuclear Medicine and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of Medicine, Shiyan, China
Xue-Yan Kui: Department of Nuclear Medicine and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of Medicine, Shiyan, China
Xiao-Yu Liu: Department of Nuclear Medicine and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of Medicine, Shiyan, China
Zhi-Jun Pei: Department of Nuclear Medicine and Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of Medicine, Shiyan, China
Zhi-Jun Pei: Hubei Key Laboratory of Embryonic Stem Cell Research, Shiyan, China

Abstract

No abstracts available.

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology